Social mobility, lifestyle and body mass index in adolescents

OBJETIVO Analisar a associação entre mobilidade social, estilo de vida e índice de massa corporal de adolescentes. MÉTODOS Estudo de coorte com 1.716 adolescentes de dez a 17 anos de idade, de ambos os sexos. Os adolescentes eram participantes de um estudo de coorte e nasceram entre 1994 e 1999. Os adolescentes foram avaliados em escolas públicas e privadas entre 2009 e 2011. O estilo de vida foi avaliado por meio de entrevista e a antropometria foi utilizada para o cálculo do índice de massa corporal. Para a classificação econômica na infância e na adolescência foram utilizados critérios preconizados pela Associação Brasileira de Empresas de Pesquisa. Mobilidade social ascendente foi considerada como aumento em pelo menos uma classe econômica no período de dez anos. Utilizou-se regressão de Poisson para estimar a associação entre a mobilidade social ascendente e os desfechos avaliados. RESULTADOS Dos adolescentes (71,4% de seguimento da coorte), 60,6% apresentaram mobilidade social ascendente. Destes, 93,6% pertenciam à classe econômica D e 99,9% à E. Maior prevalência de ascensão social foi observada para escolares de cor da pele preta (71,4%) e parda (61,9%), matriculados na escola pública (64,3%) e cujas mães apresentaram menor escolaridade na primeira avaliação (67,2%) e na reavaliação (68,7%). A mobilidade social ascendente mostrou-se associada apenas aos comportamentos sedentários (p = 0,02) após ajuste para variáveis de confusão. A classe econômica na infância mostrou-se mais associada aos desfechos avaliados do que a mobilidade social ascendente. CONCLUSÕES A mobilidade social ascendente não mostrou associação com a maioria dos desfechos avaliados, possivelmente por ter sido discreta e porque o período considerado no estudo pode não ter sido suficiente para refletir mudanças substanciais no estilo de vida e no índice de massa corporal dos adolescentes.OBJETIVO Analizar la asociación entre la movilidad social, estilo de vida e índice de masa corporal en adolescentes. MÉTODOS Estudio de cohorte con 1.716 adolescentes de diez a 17 años de edad, de ambos sexos. Los adolescentes participaban de un estudio de cohorte y nacieron entre 1994 y 1999. Los adolescentes fueron evaluados en escuelas públicas y privadas entre 2009 y 2011. El estilo de vida fue evaluado por medio de entrevista y la antropometría fue utilizada para el cálculo del índice de masa corporal. Para la clasificación económica en la infancia y en la adolescencia se utilizaron criterios recomendados por la Asociación Brasileña de Empresas de Investigación. La movilidad social ascendente fue considerada como aumento en al menos una clase económica en el período de diez años. Se utilizó regresión de Poisson para estimar la asociación entre la movilidad social ascendente y los resultados evaluados. RESULTADOS De los adolescentes (71,4% de seguimiento de la cohorte), 60,6% presentaron movilidad social ascendente. De estos, 93,6% pertenecían a la clase económica D y 99,9% a la E. La mayor prevalencia de ascensión social fue observada en escolares con color de piel negra (71,4%) y parda (61,9%), matriculados en la escuela pública (64,3%) y cuyas madres presentaban menor escolaridad en la primera evaluación (67,2%) y en la reevaluación (68,7%). La movilidad social ascendente estuvo asociada sólo con los comportamientos sedentarios (p=0,02) posterior al ajuste para variables de confusión. La clase económica en la infancia se mostró más asociada con los resultados evaluados en comparación con la movilidad social ascendente. CONCLUSIONES La movilidad social ascendente no mostró asociación con la mayoría de los resultados evaluados, posiblemente por haber sido discreta y porque el período considerado en el estudio pudo no haber sido suficiente para reflejar cambios sustanciales en el estilo de vida y en el índice de masa corporal de los adolescentes.OBJECTIVE To analyze the association between social mobility, lifestyle and body mass index in adolescents. METHODS A cohort study of 1,716 adolescents aged 10 to 17 years of both sexes. The adolescents were participants in a cohort study and were born between 1994 and 1999. The adolescents, from public and private schools, were assessed between 2009 and 2011. Lifestyle was assessed by interview and anthropometry was used to calculatebody mass index. For the economic classification, both at pre-school age and in adolescence, the criteria recommended by the Brazilian Association of Research Companies were used. Upward social mobility was categorized as an increase by at least one class in economic status within a 10-year-period. Poisson regression was used to estimate the association between upward social mobility and the outcomes assessed. RESULTS Among all respondents (71.4% follow-up of the cohort), 60.6% had upward social mobility. Among these, 93.6% belonged to socioeconomic class D and 99.9% to economy class E. Higher prevalence of social mobility was observed for students with black skin (71.4%) and mulatto students (61.9%) enrolled in public schools (64.3%) whose mothers had less schooling in the first evaluation (67.2%) and revaluation (68.7%). After adjustment for confounding variables, upward social mobility was associated only with sedentary behavior (p = 0.02). The socioeconomic class in childhood was more associated with the outcomes assessed than was upward mobility. CONCLUSIONS Upward social mobility was not associated with most of the outcomes evaluated, possibly as it is discreet and because the period considered in the study may not have been sufficient to reflect substantial changes in lifestyle and body mass index in adolescents

ALTERNATIVAS DE FORMULAÇÕES INÉDITAS DE PROTETORES SOLARES NATURAIS: EXTRATO DAS SEMENTES DE MORINGA OLEÍFERA COM EXTRATOS ETANÓLICOS DE PRÓPOLIS.

Repeated or intense exposure to UV (ultraviolet) radiation causes skin changes by generating reactive oxygen species (ROS), which are harmful to tissues, causing burns, spots, erythema, photoaging and DNA mutations. The use of sunscreens is a means of preventing or reducing the effects of these exposures, as they have the ability to reflect and/or absorb them. Protectors can be of synthetic or natural origin. The development of actives capable of increasing the efficiency of sunscreens, especially those of plant origin, represents a growing demand in cosmetology. Moringa oleifera is a plant with varied pharmacological applications, it has a fast growth in tropical countries, and it is present in the Brazilian northeast and north of the state of Minas Gerais. Based on this, this study aims to evaluate the use of raw materials of natural origin as photoprotective agents, looking for trends in the consumer market. For this, novel formulations of dichloromethane extract of Moringa oleífera seeds, in association with different ethanolic extracts of propolis, were studied in relation to the photoprotective capacity. Regarding the propolis extracts (green, red and brown) 70% ethanolic were used. The photoprotective activity was studied in vitro. The results showed significant increases in FPS for the formulations. The high increase in sun protection was verified in green propolis, justified by the greater amount of flavonoids it presents. We concluded that the propolis extracts incorporated in the formulations with dichloromethane extract in the Moringa oleifera seeds showed a synergism in the intensification of the sun protection factor.La exposición repetida o intensa a la radiación UV (ultravioleta) provoca cambios en la piel debido a la generación de especies reactivas de oxígeno (ROS), las cuales son dañinas para los tejidos, provocando quemaduras, manchas, eritema, fotoenvejecimiento y mutaciones en el ADN. El uso de protectores solares es un medio para prevenir o reducir los efectos de estas exposiciones, ya que tienen la capacidad de reflejarlos y/o absorberlos. Los protectores pueden ser de origen sintético o natural. El desarrollo de activos capaces de aumentar la eficacia de los fotoprotectores, especialmente los de origen vegetal, representa una demanda creciente en cosmetología. Moringa oleifera es una planta con variadas aplicaciones farmacológicas, presenta un rápido crecimiento en los países tropicales y está presente en el noreste brasileño y norte del estado de Minas Gerais. En base a esto, este estudio tiene como objetivo evaluar el uso de materias primas de origen natural como agentes fotoprotectores, buscando tendencias en el mercado de consumo. Para ello, se estudiaron formulaciones inéditas de extracto de diclorometano de semillas de Moringa oleifera, en asociación con diferentes extractos etanólicos de propóleo, en relación a su capacidad fotoprotectora. En cuanto a los extractos de propóleos (verde, rojo y pardo) se utilizaron etanólicos al 70%. La actividad fotoprotectora se estudió in vitro. Los resultados mostraron aumentos significativos de SPF para las formulaciones. En el propóleo verde se verificó el alto incremento de la protección solar, justificado por la mayor cantidad de flavonoides que presenta. Concluimos que los extractos de propóleo incorporados en las formulaciones con extracto de diclorometano en semillas de Moringa oleifera mostraron un sinergismo en la intensificación del factor de protección solar.Exposições repetidas ou intensas a radiações UV (ultravioleta) causam alterações cutâneas pela geração das espécies reativas do oxigênio (EROs), danosas aos tecidos, causando queimaduras, manchas, eritemas, fotoenvelhecimento e mutações no DNA. O uso de protetores solares é um meio de prevenir ou reduzir os efeitos destas exposições, por terem a capacidade de refletir e/ou absorvé-las. Os protetores podem ser de origem sintética ou natural. O desenvolvimento de ativos, capazes de aumentar à eficiência de protetores solares, principalmente os de origem vegetal, representa uma demanda crescente da cosmetologia. Moringa oleifera é uma planta com variadas aplicações farmacológicas, apresenta um rápido crescimento nos países tropicais, e está presente no nordeste brasileiro e norte do estado de Minas Gerais. Com base nisso, esse estudo visa avaliar a utilização de matérias primas de origem natural como agentes fotoprotetores, buscando as tendências do mercado consumidor. Para isso, formulações inéditas de extrato diclorometano de sementes de Moringa oleífera, em associação com diferentes extratos etanólicos de própolis, foram estudadas em relação à capacidade fotoprotetora. Em relação aos extratos de própolis (verde, vermelha e marrom) foram usados os etanólicos 70%. A atividade fotoprotetora foi estudada in vitro. Os resultados mostraram aumentos significativos de FPS para as formulações. O incremento elevado na proteção solar foi verificado na própolis verde, justificado pela maior quantidade de flavonóides que ela apresenta. Concluímos que os extratos de própolis incorporados nas formulações com extrato de diclorometano nas sementes Moringa oleifera apresentaram um sinergismo na intensificação do fator de proteção solar

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt

A social and ecological assessment of tropical land uses at multiple scales: the Sustainable Amazon Network

Science has a critical role to play in guiding more sustainable development trajectories. Here, we present the Sustainable Amazon Network (Rede Amazonia Sustentavel, RAS): a multidisciplinary research initiative involving more than 30 partner organizations working to assess both social and ecological dimensions of land-use sustainability in eastern Brazilian Amazonia. The research approach adopted by RAS offers three advantages for addressing land-use sustainability problems: (i) the collection of synchronized and co-located ecological and socioeconomic data across broad gradients of past and present human use; (ii) a nested sampling design to aid comparison of ecological and socioeconomic conditions associated with different land uses across local, landscape and regional scales; and (iii) a strong engagement with a wide variety of actors and non-research institutions. Here, we elaborate on these key features, and identify the ways in which RAS can help in highlighting those problems in most urgent need of attention, and in guiding improvements in land-use sustainability in Amazonia and elsewhere in the tropics. We also discuss some of the practical lessons, limitations and realities faced during the development of the RAS initiative so far.Keywords: Social–ecological systems, Tropical forests, Land use, Interdisciplinary research, Sustainability, Trade-off

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings